Troxyca extended-release tablets are intended to treat patients that require daily, long-term opioid treatment to manage severe pain.
The tablets contain pellets of oxycodone hydrochloride, an opioid agonist, that surround naltrexone hydrochloride, an opioid antagonist.
When the pill is taken whole, the naltrexone remains sequestered and patients receive an extended-release dose of oxycodone. However, if the pill is crushed, the pellets release naltrexone, which counteracts the effects of the oxycodone.
Pfizer warns that while the drug is intended to reduce inappropriate use of the drug, opioid abuse is still possible.
The New York-based drugmaker did not say when the product would launch.
More articles on supply chain:
4 ways the FDA is contributing to high generic drug costs
Supply chain tip of the week: Replenish your inventory the right way
Researchers develop new method to transfer device data to smartphones
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.